Publications 2004
Burger H, Nooter K
Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib.
Cell Cycle. 2004 Dec;3(12):1502-5
Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
Blood. 2004 Nov 1;104(9):2940-2
de Bruijn P, Willems EW, Loos WJ, Verweij J, Sparreboom A
Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.
Anal Biochem. 2004 May 1;328(1):84-6
de Jonge MJ, Droz JP, Paz-Ares L, van Oosterom AT, de Wit R, Chollet P, Baron B, Lacombe D, Mettinger K, Fumoleau P,
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
Invest New Drugs. 2004 Aug;22(3):329-33
de Jonge MJ, Kaye S, Verweij J, Brock C, Reade S, Scurr M, van Doorn L, Verheij C, Loos W, Brindley C, Mistry P, Cooper M, Judson I
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.
Br J Cancer. 2004 Oct 18;91(8):1459-65
De Jong FA, Mathijssen RH, Verweij J
Limited potential of hepatic arterial infusion of irinotecan.
J Chemother. 2004 Nov;16 Suppl 5:48-50
de Jong FA, Mathijssen RH, Xie R, Verweij J, Sparreboom A
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4068-71
de Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A
Population pharmacokinetics of cisplatin in adult cancer patients.
Cancer Chemother Pharmacol. 2004 Aug;54(2):105-12
de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
Eur J Cancer. 2004 Feb;40(3):403-10
Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Clin Pharmacol Ther. 2004 May;75(5):448-54
Eskens FA
Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Br J Cancer. 2004 Jan 12;90(1):1-7
Gratama JW, Kern F
Flow cytometric enumeration of antigen-specific T lymphocytes.
Cytometry A. 2004 Mar;58(1):79-86
Hollestelle A, Schutte M
Representational difference analysis as a tool in the search for new tumor suppressor genes.
Methods Mol Med. 2005;103:143-59
Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG,
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
N Engl J Med. 2004 Jul 29;351(5):427-37
Kruit WH, Stoter G, Klijn JG
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
Anticancer Drugs. 2004 Oct;15(9):843-7
Lamers CH, Sleijfer S, Willemsen RA, Debets R, Kruit WH, Gratama JW, Stoter G
Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.
J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):134-40
Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
J Natl Cancer Inst. 2004 Nov 3;96(21):1585-92
Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Cancer Res. 2004 Jul 1;64(13):4563-8
Planting A, van der Gaast A, Schöffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J
A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
Cancer Chemother Pharmacol. 2005 Feb;55(2):136-42
Polee MB, Sparreboom A, Eskens FA, Hoekstra R, van de Schaaf J, Verweij J, Stoter G, van der Gaast A
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer.
Clin Cancer Res. 2004 Mar 15;10(6):1928-34
Schenk PW, Stoop H, Bokemeyer C, Mayer F, Stoter G, Oosterhuis JW, Wiemer E, Looijenga LH, Nooter K
Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1.
Neoplasia. 2004 Jul-Aug;6(4):297-301
Seynaeve C, Verhoog LC, van de Bosch LM, van Geel AN, Menke-Pluymers M, Meijers-Heijboer EJ, van den Ouweland AM, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JG, Brekelmans CT
Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
Eur J Cancer. 2004 May;40(8):1150-8
Seynaeve C, Verweij J
Targeted therapy: ready for prime time?
Cancer Treat Res. 2004;120:1-15
Sleijfer S, Kruit WH, Stoter G
Thalidomide in solid tumours: the resurrection of an old drug.
Eur J Cancer. 2004 Nov;40(16):2377-82
Soepenberg O, de Bruijn P, Verweij J, Atsumi R, Sparreboom A
Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices.
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):15-22
Soepenberg O, Sparreboom A, de Jonge MJ, Planting AS, de Heus G, Loos WJ, Hartman CM, Bowden C, Verweij J
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
Eur J Cancer. 2004 Mar;40(5):681-8
Sparreboom A, Kehrer DF, Mathijssen RH, Xie R, de Jonge MJ, de Bruijn P, Planting AS, Eskens FA, Verheij C, de Heus G, Klaren A, Zhang S, Verhaeghe T, Palmer PA, Verweij J
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
Br J Cancer. 2004 Apr 19;90(8):1508-15
ten Tije AJ, Loos WJ, Zhao M, Baker SD, Enting RH, van der Meulen H, Verweij J, Sparreboom A
Limited cerebrospinal fluid penetration of docetaxel.
Anticancer Drugs. 2004 Aug;15(7):715-8
ten Tije AJ, Smorenburg CH, Seynaeve C, Sparreboom A, Schothorst KL, Kerkhofs LG, van Reisen LG, Stoter G, Bontenbal M, Verweij J
Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.
Eur J Cancer. 2004 Feb;40(3):352-7
van Dooren S, Rijnsburger AJ, Seynaeve C, Duivenvoorden HJ, Essink-Bot ML, Tilanus-Linthorst MM, de Koning HJ, Tibben A
Psychological distress in women at increased risk for breast cancer: the role of risk perception.
Eur J Cancer. 2004 Sep;40(14):2056-63
van Zuylen L, Bridgewater J, Sparreboom A, Eskens FA, de Bruijn P, Sklenar I, Planting AS, Choi L, Bootle D, Mueller C, Ledermann JA, Verweij J
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
Clin Cancer Res. 2004 Mar 15;10(6):1949-55
Verweij J
KIT and PDGF as targets.
Cancer Treat Res. 2004;120:117-27
Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34
Verweij J, de Mulder PH, Pinedo HM
[The Dutch Health Council report on palliative chemotherapy: possible confusion on ideas]
Ned Tijdschr Geneeskd. 2004 Apr 3;148(14):651-4